OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported full-year 2024 financial ...

OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today provided a regulatory update for its ...

Documentary focusing on canine comparative oncology will premiere at the Los Angeles AMC Century City on April 3rd OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical ...

We recently published a list of 10 Penny Stocks With Huge Upside Potential According To Analysts. In this article, we are ...

NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

OS Therapies (OSTX) announced that it has scheduled a Scientific Advice Meeting in the third quarter of 2025 to discuss the Innovative Licensing and Access Pathway with the United Kingdom’s ...

Patients with metastatic NSCLC may benefit from continuing on pembrolizumab-based treatment after progressing on that ...

In this article, we are going to take a look at where OS Therapies Incorporated (NYSEAMERICAN:OSTX) stands against other penny stocks with the biggest upside potential. Penny stocks trade below $5 ...

NEW YORK, March 25, 2025--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, ...